Alcohol Withdrawal Syndrome

Definition

Alcohol withdrawal syndrome (AWS) is the clinical syndrome that may occur when a person with alcohol dependence abruptly reduces or stops alcohol consumption. ^[8]B3b The term refers to a clinically recognized withdrawal state rather than simply a history of alcohol use, a positive blood alcohol concentration, or a diagnosis of alcohol use disorder (AUD). ^{[2]B3b[3]B2c[4]B3b[8]B3b} In a treatment cohort of patients with DSM-5 AUD, AWS was assessed using DSM-5 criteria; the study description specifies the presence of ≥2 clinical signs or symptoms as part of the operational definition. ^[4]B3b

AWS may be present at hospital admission or may develop later during hospitalization. ^[8]B3b This distinction is clinically important because hospitalized patients with alcohol dependence may initially appear free of withdrawal and subsequently develop clinically evident AWS. ^[8]B3b Trauma populations are also commonly classified into separate groups according to blood alcohol level or documented AWS, illustrating that acute alcohol exposure and withdrawal are treated as distinct clinical classifications in hospital research. ^[2]B3b

Classification by clinical recognition and setting

The cited literature primarily classifies AWS according to whether it is clinically recognized, when it occurs, its severity, and the care setting required, rather than by a single universally accepted grading system. ^[3]B2c[8]B3b “Clinically recognized inpatient AWS” is a documentation-based category identified from hospital diagnostic or procedure codes; its reported prevalence can vary according to hospital, geographic region, admitting specialty, and other inpatient diagnoses. ^[3]B2c Consequently, coded prevalence should not be interpreted as the complete biological prevalence of withdrawal. ^[3]B2c

A practical temporal classification is therefore: (1) AWS present at presentation, and (2) AWS developing after admission. ^[8]B3b A practical severity classification distinguishes uncomplicated withdrawal from severe or complicated withdrawal requiring intensive monitoring or escalation of therapy, although the cited studies do not establish one universal boundary between these categories. ^{[1]B3b[7]B3b[9]B3b} Delirium tremens (DT) is named separately from AWS in hospital case definitions and may be included alongside AWS when identifying severe withdrawal cases. ^[1]B3b

“Resistant alcohol withdrawal” (RAW) denotes a severe withdrawal phenotype that does not respond adequately to benzodiazepines despite escalating doses. ^[9]B3b RAW is associated with greater use of mechanical ventilation, more nosocomial pneumonia, and longer ICU stay in the multicenter study cited here. ^[9]B3b ICU-specific AWS protocols have been studied as a distinct management context, including protocols intended to reduce the need for mechanical ventilation. ^[7]B3b

AWS may also be classified by important clinical context or diagnostic confounding. Patients with traumatic brain injury (TBI) can have signs and symptoms that resemble AWS, while treatment priorities differ because benzodiazepines and other central nervous system depressants may be undesirable in TBI. ^[119]C In this setting, a CIWA-based classification may be difficult to interpret and may lead to potentially inappropriate treatment if AWS is not distinguished from neurologic injury. ^[119]C Cardiac complications can provide another clinically relevant modifier: arrhythmias are documented during AWS hospitalizations and are associated with increased mortality in a nationwide analysis. ^[120]D

Assessment terminology and nomenclature

The Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar), is an assessment instrument and treatment-guidance framework, not a standalone etiologic definition of AWS. ^[119]C It grades withdrawal-related signs and symptoms and is used to guide the addition or titration of central nervous system depressants, most commonly benzodiazepines. ^[119]C A hospital-wide CIWA-Ar protocol is therefore best understood as a symptom-based management protocol rather than a replacement for clinical diagnosis. ^[6]B3b

The literature also uses “symptom-triggered,” “fixed-dose,” and “front-loading” to describe benzodiazepine treatment strategies, not different diseases. ^[5]B2c In the national Veterans Health Administration cohort, these strategies were explicitly categorized separately among hospitalized medical inpatients treated for AWS. ^[5]B2c Simplified instruments may be described as derivatives of CIWA-Ar; the Highland Alcohol Withdrawal Protocol, for example, was evaluated as a simplified tool for symptom-triggered treatment. ^[1]B3b ICU-specific symptom-triggered protocols represent a setting-specific implementation of the same general treatment concept. ^[7]B3b

AUDIT-PC is a screening or risk-prediction term rather than a diagnostic synonym for AWS. ^[8]B3b It was evaluated for its ability to predict subsequent AWS among hospitalized medical-surgical patients, reflecting the distinction between identifying patients at risk and diagnosing withdrawal after clinical signs emerge. ^[8]B3b Similarly, “alcohol-related trauma,” blood alcohol positivity, AUD, alcohol dependence, AWS, DT, and RAW should be retained as related but non-interchangeable terms. ^{[2]B3b[4]B3b[8]B3b[9]B3b}

Core neuroadaptation

Alcohol withdrawal syndrome (AWS) reflects central nervous system hyperexcitation after a reduction or cessation of alcohol exposure.^[22]D5 Chronic alcohol use produces neuroadaptive changes involving inhibitory γ-aminobutyric acid (GABA) and excitatory glutamatergic systems; when alcohol is removed, persistent excitatory drive and inadequate inhibitory compensation contribute to withdrawal manifestations.^[124]D Increased central N-methyl-D-aspartate (NMDA) glutamate transmission has been specifically identified in AWS.^[17]A1b The resulting imbalance provides a neurobiological basis for tremor, autonomic activation, anxiety, agitation, hallucinations, seizures, and delirium tremens.^[22]D5

Alcohol withdrawal can progress through recognizable clinical stages, including early withdrawal symptoms, hallucinations, seizures, and delirium tremens.^[22]D5 Severe AWS is therefore not simply a psychological reaction to cessation: it is a potentially life-threatening hyperexcitable state requiring assessment for neurological and medical complications.^[22]D5

GABAergic and glutamatergic mechanisms

The GABA/NMDA imbalance is central to both acute and persistent withdrawal biology.^[124]D This framework explains why treatments that enhance inhibitory signaling or reduce excitatory transmission have been investigated in AWS.^{[17]A1b[22]D5} Benzodiazepines remain the standard pharmacological treatment across the phases of AWS because of their GABA-receptor activity.^[21]D5[22]D5 Propofol has a distinct sedative mechanism that includes GABA-A receptor agonism and reduction of glutamatergic activity through NMDA-receptor blockade; it has consequently been studied as an adjunct in refractory AWS.^[23]D5

The NMDA hypothesis has not translated uniformly into clinical benefit for every antagonist. Dextromethorphan is a low-affinity, noncompetitive NMDA antagonist with proposed neuroprotective properties, but a randomized, double-blind, placebo-controlled preliminary trial found no efficacy for management of acute AWS.^[17]A1b This result indicates that NMDA overactivity is biologically relevant but that pharmacological NMDA antagonism alone may not adequately control the full withdrawal syndrome.^[17]A1b

Baclofen has been evaluated because of its potential to reduce AWS symptoms and was compared directly with diazepam in a randomized study.^[15]A1b Cochrane reviews published between 2011 and 2019 assessed baclofen for AWS, but the available evidence base remained limited and was intended to evaluate efficacy and safety rather than establish baclofen as a replacement for benzodiazepines.^{[10]A1a[11]A1a[12]A1a[13]A1a[14]A1a} Other GABAergic or sedative strategies have also been examined: gamma-hydroxybutyric acid was compared with clomethiazole in a randomized intensive-care study of severe AWS with concomitant medical disease, while oxazepam and clomethiazole were compared retrospectively in alcohol-dependent patients.^[18]A1b[121]

Autonomic and adrenergic hyperactivity

Withdrawal-related autonomic activation involves altered cardiovascular and β-adrenergic responses.^[19]C4 In alcohol-dependent subjects, propranolol produced different negative chronotropic and hypotensive effects during withdrawal than during remission, and the pre-treatment haemodynamic state was the strongest modifier of the response.^[19]C4 Daily alcohol consumption also predicted part of the response, supporting a relationship between exposure history, withdrawal physiology, and adrenergic regulation.^[19]C4 These findings help explain why tachycardia, hypertension, sweating, tremor, and other autonomic signs are clinically prominent, although β-adrenergic blockade does not address the core excitatory CNS process.^[19]C4[22]D5

Dexmedetomidine has been evaluated as an adjunct to benzodiazepine therapy in adult intensive-care patients because AWS delirium may persist when the underlying inhibitory–excitatory imbalance is inadequately controlled.^[109]A1a The evidence concerns reduction of delirium severity when dexmedetomidine is added to benzodiazepines, rather than replacement of primary GABAergic treatment.^[109]A1a

Post-acute and protracted withdrawal

Neuroadaptation may persist beyond the acute withdrawal period.^[16]D5[124]D Post-acute alcohol withdrawal is characterized predominantly by negative affect that may begin during early abstinence and persist for 4–6 months or longer.^[16]D5 Reported symptoms include anxiety, dysphoria, anhedonia, sleep disturbance, cognitive impairment, craving, and irritability; these symptoms have been associated with recurrent alcohol consumption.^[16]D5 Protracted withdrawal has been described as a poorly defined continuation of substance-specific symptoms—including anxiety, irritability, mood instability, insomnia, and craving—after the expected acute AWS time frame.^[124]D

The proposed biology of protracted withdrawal remains focused on persistent GABA and NMDA neuroadaptation.^[124]D Accordingly, medications used for long-term alcohol-use-disorder relapse prevention, including naltrexone, nalmefene, and disulfiram, may not suppress all protracted-withdrawal symptoms.^[124]D Gabapentin has been investigated as a benzodiazepine-sparing strategy in acute inpatient withdrawal, but retrospective evidence remains limited.^[122]

Emerging and hypothesized mechanisms

Pyridoxal-5′-phosphate is a cofactor for glutamic acid decarboxylase, the rate-limiting enzyme that converts glutamate to GABA.^[123]D A 2026 hypothesis paper proposes that deficiency of this active vitamin B6 form could worsen the glutamatergic/GABAergic imbalance in AWS and that repletion might improve outcomes; this remains hypothesis-level evidence rather than established treatment guidance.^[123]D Sigma-1 receptor mechanisms are another emerging area: preclinical evidence suggests that sigma-1 receptor antagonists may reduce alcohol intake, alcohol-seeking behavior, and related cognitive or motor abnormalities, but clinical efficacy in AWS has not been established.^[20]D5

Overall, AWS is best understood as a dynamic disorder of inhibitory–excitatory neuroadaptation with superimposed autonomic dysregulation and, in some patients, prolonged affective, cognitive, sleep, and craving-related symptoms.^{[16]D5[19]C4[22]D5[124]D}

Epidemiology

Alcohol withdrawal syndrome (AWS) is a clinically important complication of alcohol use disorder (AUD) and is a common reason for emergency-department evaluation and hospital admission.^[126][127] Contemporary epidemiologic estimates vary according to case definition, coding practices, clinical setting, and whether repeated hospitalizations are counted as separate events.^[127][128] In a large United States emergency-department study covering 2016–2023, AWS presentations were identified from 242,804,798 emergency visits using ICD-10 codes; the study evaluated temporal changes in AWS frequency, admission, length of stay, and medication treatment.^[127] A separate Kaiser Permanente Washington cohort evaluated the incidence and proportional incidence of hospitalizations involving AWS among adults receiving primary care and annual alcohol screening between July 2018 and June 2022.^[128]

AWS occurs across adult age groups. In a hospital cohort of 10,092 patients aged 21 years or older, 30.2% were women; the largest age group was 40–64 years, followed by 21–39 years, 65–74 years, and ≥75 years.^[36]B2b The same study specifically examined age- and sex-related differences in AWS prevalence, clinical manifestations, and hospital course, indicating that demographic variation should be considered when interpreting observed rates and severity.^[36]B2b In a tertiary alcohol-related disease unit, women represented 26.2% of 907 admissions for AUD between 2004 and 2022, and the analysis included AWS prevalence and severity as clinical outcomes.^[125]

Repeated hospitalization is an important epidemiologic feature of AWS and AUD. A systematic review and meta-analysis specifically examined readmission after inpatient alcohol detoxification, including variation by study design and hospital setting and the risk and protective factors associated with rehospitalization.^[175]C However, the supplied abstract does not provide the pooled readmission estimate; therefore, a single generalizable readmission percentage cannot be stated from this evidence alone.^[175]C

Etiology and clinical context

The supplied literature consistently places AWS in the context of AUD, heavy alcohol exposure, and hospitalization for an acute medical or traumatic illness.^[126][128] In trauma populations, the investigators defined heavy drinking as daily alcohol consumption or >7 drinks per week and evaluated its association with subsequent AWS.^[31]B2b This supports recent heavy alcohol use as a clinically relevant risk marker, although the retrospective design does not establish that this threshold is biologically sufficient or necessary for AWS in every patient.^[31]B2b

AWS is also observed in patients hospitalized with alcohol-associated hepatitis (AH). A multinational retrospective cohort from five centers in Spain and the United States evaluated AWS among patients hospitalized with AH from January 2016 through January 2021, using clinical criteria and sedative treatment to identify AWS and examining predictors, management, and mortality.^[30]B2b This population illustrates the overlap between alcohol-related liver disease and AWS, but the study’s case definition and retrospective design limit direct extrapolation to all patients with AUD.^[30]B2b Delirium tremens (DT) is a clinically consequential manifestation in this setting: a Japanese hospital study of 88 patients with alcoholic hepatitis reviewed DT, risk factors, and outcomes, and highlighted the possibility that loss of follow-up after DT may lead to missed critical events.^[40]C4

Risk factors and high-risk populations

Risk assessment should integrate recent drinking pattern, prior withdrawal history when available, acute illness, and the care setting.^{[31]B2b[30]B2b} Trauma patients were specifically studied because AWS risk was relatively low overall but difficult to predict from single variables; the study therefore evaluated multifactorial screening strategies and excluded patients with severe traumatic brain injury defined as Glasgow Coma Scale ≤8.^[31]B2b The exclusion means that the reported associations should not be applied automatically to patients with severe traumatic brain injury.^[31]B2b

Alcohol-associated hepatitis is a high-risk clinical context because AWS may coexist with substantial hepatic disease severity and may influence hospital outcomes; the multinational cohort adjusted predictor analyses for demographic variables and disease severity.^[30]B2b Critically ill patients represent another high-acuity subgroup in which AWS management has been studied, including trials and retrospective cohorts of adjunctive dexmedetomidine, phenobarbital, and other therapies.^{[28]A1a[114]B3b[126][131][133]} These treatment studies confirm that severe or difficult-to-control AWS is sufficiently common in intensive-care and hospitalized populations to prompt escalation beyond benzodiazepine monotherapy, but they do not independently quantify population-level incidence or prove specific causal risk factors.^{[28]A1a[114]B3b[126][131][133]}

Older age and sex may modify presentation and hospital course rather than simply determining whether AWS occurs.^[36]B2b Sex-specific analyses of hospitalized AUD patients found that research has historically focused predominantly on men, while women constituted approximately one-quarter of the studied cohorts.^[125] Accordingly, apparently lower observed prevalence among women may reflect differences in underlying AUD prevalence, referral patterns, case ascertainment, or treatment access rather than absence of AWS risk.^[125][36]B2b

Evidence limitations

Most supplied epidemiologic evidence is retrospective and based on hospital records, diagnostic codes, protocol enrollment, or treatment exposure.^{[6]B3b[30]B2b[31]B2b[36]B2b[40]C4[125][127][128]} Such designs may overrepresent severe cases, patients with recurrent admissions, and individuals treated in specialist or tertiary hospitals.^[175]C[127] Protocol-based studies using CIWA-Ar or other withdrawal scales identify clinically recognized AWS but may not capture untreated, undertreated, or atypical presentations.^[6]B3b[130] Conversely, studies defining AWS partly by sedative use may introduce ascertainment bias because treatment decisions can influence case classification.^[30]B2b These limitations support using demographic and clinical factors as risk indicators rather than as definitive diagnostic criteria.^{[30]B2b[31]B2b[36]B2b[175]C}

Overview

Alcohol withdrawal syndrome (AWS) is a potentially life-threatening complication of abrupt reduction or cessation of alcohol exposure in people with chronic, heavy alcohol consumption or alcohol use disorder (AUD). Clinical severity ranges from mild symptoms to complicated withdrawal characterized by seizures or delirium tremens (DT). ^{[44]A1c[46]A1a[50]B2a[137]} Most patients who develop withdrawal have mild illness, whereas a smaller proportion develop seizures or DT requiring hospital-level care. ^[137] AWS is managed across emergency-department, inpatient, and intensive-care settings, and its assessment is particularly important when alcohol is no longer available after admission. ^{[44]A1c[109]A1a}

Phases and symptom domains

AWS has been described as having acute, early, and protracted phases. ^[47]A1a During the protracted phase, some symptoms may persist for weeks, months, or, in some reports, years after drinking cessation. ^[47]A1a The best-supported protracted symptoms are craving, sleep disturbance, and anhedonia. ^[47]A1a In a systematic review, pooled craving scores measured with the Obsessive Compulsive Drinking Scale decreased from 24.2 at baseline to 18.8 after 1 week, 10.3 after 1 month, and 9.7 after 3 months, indicating improvement over time but persistence beyond the initial withdrawal period. ^[47]A1a

Acute withdrawal severity is commonly quantified with the Clinical Institute Withdrawal Assessment for Alcohol–revised (CIWA-Ar), including in clinical trials of uncomplicated AWS and inpatient AWS. ^{[49]A1b[52]A1b} In the magnesium randomized trial, patients were eligible when their baseline CIWA-Ar score was greater than 8, demonstrating the use of this threshold to identify clinically significant withdrawal in that study. ^[52]A1b CIWA-Ar is a symptom-severity instrument rather than a validated tool for predicting who will subsequently develop AWS. ^[50]B2a Its interpretation may be unreliable when symptoms overlap with other conditions; traumatic brain injury (TBI) and AWS can produce similar clinical findings, while the treatments for the two conditions may differ substantially. ^[119]C

Complicated withdrawal

The most clinically important complications are alcohol-related seizures and DT. ^{[50]B2a[137][139]C} Severe AWS has been operationalized as a composite of DT, withdrawal seizure, or requirement for high-dose benzodiazepine treatment. ^[137] Alcohol-related seizures are a major consequence of AWS and have been specifically studied in relation to DT and overall withdrawal severity. ^[139]C Risk-assessment approaches—including the Prediction of Alcohol Withdrawal Severity Scale (PAWSS), the Alcohol Withdrawal Triage Tool (AWTT), and machine-learning models—were developed to identify patients at risk for moderate-to-severe withdrawal, DT, seizures, or hospital admission rather than merely describing symptoms after they have developed. ^{[50]B2a[93]B2c[137]}

Associated and alternative presentations

Clinical deterioration during AWS may coexist with medical complications or alternative diagnoses. In a population-based cohort of alcoholic patients with community-acquired bacterial meningitis, seizures were present at presentation in 18%, and 23% had co-existing pneumonia; the leading organisms were Streptococcus pneumoniae in 76%, Listeria monocytogenes in 8%, and Neisseria meningitidis in 6% of cases. ^[48]B2b These findings support evaluation for infection when the presentation is atypical, includes focal or meningeal features, or fails to follow the expected withdrawal course. ^[48]B2b

Alcohol-related nutritional disease can also mimic or accompany withdrawal-related neuropsychiatric or gastrointestinal symptoms. In a retrospective series of 16 patients with alcoholic pellagra, the principal complaints were skin lesions in six patients, diarrhea in six, and mental disorders in four; the classical triad was not consistently present. ^[51]C4 Therefore, rash, diarrhea, or prominent cognitive or behavioral symptoms should not automatically be attributed to AWS. ^[51]C4

Alcohol withdrawal may also interact with chronic pain. A 2024 review described a reciprocal relationship between AUD and chronic pain in which alcohol used for analgesia can rapidly produce acute tolerance, potentially triggering further alcohol use and withdrawal-related worsening of pain. ^[29]D5 This interaction may complicate symptom reporting and clinical assessment. ^[29]D5

Clinical assessment priorities

In adults presenting to the emergency department with suspected AWS or AUD, assessment should establish the timing and pattern of alcohol reduction, identify prior withdrawal complications, and evaluate for seizure, delirium, trauma, infection, nutritional disease, and other causes of altered mental status. ^{[44]A1c[48]B2b[50]B2a[119]C[137]} The presence of delirium, seizure, severe or escalating withdrawal, or inability to assess symptoms reliably should prompt consideration of monitored inpatient or intensive-care management. ^[44]A1c[137] Patients with TBI, altered mental status unrelated to AWS, or other competing diagnoses require particular caution because symptom scales may overestimate or misclassify withdrawal severity. ^[119]C[133]

Diagnosis requires ≥2 symptoms (e.g., tremor, tachycardia, insomnia) after reducing intake ^[56]A1c. Workup must rule out mimics like meningitis , hypoglycemia , or Wernicke encephalopathy ^{[48]B2b[53]A1c}. CIWA-Ar is the gold standard for monitoring severity ^[55]A1a. PAWSS score ≥4 has a likelihood ratio (LR) of 174 for severe withdrawal ^[27]A1a.

Pearl: A PAWSS score of 4 or more is the most robust predictor of severe withdrawal (LR 174), and its use should trigger aggressive prophylaxis or ICU-level monitoring ^[27]A1a.

Scope and clinical framing

Alcohol withdrawal syndrome (AWS) is a potentially life-threatening complication of alcohol use disorder and may occur across a broad spectrum of severity, from autonomic and neuropsychiatric symptoms to seizures, delirium, and a need for high-intensity or critical care. ^{[65]A1c[143][144]} The 2020 American Society of Addiction Medicine (ASAM) guideline addresses hospitalized adults with AWS of any severity and provides the principal framework for assessment, monitoring, and treatment selection. ^[65]A1c

Severity should be assessed dynamically rather than inferred from a single symptom score. The Clinical Institute Withdrawal Assessment for Alcohol—Revised (CIWA-Ar) is widely used to quantify symptoms and follow their course, but it is not a substitute for clinical judgment when patients are delirious, unable to communicate reliably, sedated, mechanically ventilated, or have competing medical or neurologic illness. ^[55]A1a[144] A systematic review and meta-analysis found that aggregated CIWA-Ar scores generally track the clinical course of AWS and can support treatment monitoring, although heterogeneity among studies limits precise interpretation of score changes and comparisons between benzodiazepine and non-benzodiazepine regimens. ^[55]A1a

Course and severity specifiers

The clinical course may evolve after presentation, particularly as alcohol exposure declines or hospitalization interrupts usual consumption. Patients may progress from early withdrawal manifestations to more severe withdrawal requiring escalating medication, closer observation, or transfer to a higher level of care. ^[65]A1c[144] In a multicenter observational study of hospitalized adults, CIWA-Ar scores and medication exposure were examined as markers of patients who received high-intensity care; the study supports using both symptom trajectory and treatment requirements, rather than CIWA-Ar alone, when identifying patients at risk for escalation. ^[144]

A CIWA-Ar baseline score above 8 was used to enroll inpatients in a multicenter randomized trial of adjunctive oral magnesium, indicating clinically meaningful withdrawal symptoms in that study population; this threshold should not be treated as a universal definition of severe AWS. ^[52]A1b In pregnancy or early postpartum, available evidence is limited but concerning: a retrospective Mayo Clinic series of eight pregnant patients treated under a CIWA-Ar protocol reported a median peak CIWA-Ar score of 17 with an interquartile range of 14, consistent with substantial withdrawal severity in this small cohort. ^[140]C The study also evaluated maternal and fetal outcomes, but its sample size and retrospective design preclude generalization. ^[140]C

Seizures and delirium represent clinically important complicated forms of AWS and require urgent assessment for alternative or coexisting causes. ^{[32]A1a[65]A1c} Evidence reviews of inpatient anticonvulsants specifically included adults with moderate-to-severe AWS and evaluated symptom improvement, seizures, delirium tremens, and adverse events; however, the available evidence was heterogeneous and does not establish anticonvulsants as a replacement for standard treatment of complicated withdrawal. ^[32]A1a Reviews of non-benzodiazepine and non-barbiturate therapies similarly identified potential alternatives but emphasized limitations in the evidence, particularly for moderate-to-severe AWS and settings in which oversedation is hazardous. ^[68]B2a

Risk stratification

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) is a clinically useful risk tool for identifying patients at risk for complicated withdrawal. In a randomized hospital trial, adults with PAWSS ≥4 were classified as having a risk of complicated AWS and randomized to fixed-dose gabapentin or CIWA-Ar-directed benzodiazepines. ^[70]B2b A separate hospital screening protocol used universal PAWSS screening, followed by Glasgow Modified Alcohol Withdrawal Scale assessment and protocolized treatment; this retrospective evaluation examined length of stay, benzodiazepine exposure, and AWS-attributable adverse events. ^[143] PAWSS should therefore be used to identify risk before severe symptoms emerge, while serial clinical assessment remains necessary to detect actual progression. ^{[65]A1c[70]B2b[143]}

Risk is also context dependent. In trauma populations, multifactor screening strategies were developed because the overall proportion of trauma patients developing AWS was low and individual risk conditions were difficult to define precisely; examined variables included heavy drinking, defined in that study as daily drinking or more than seven drinks per week, and blood alcohol concentration. ^[31]B2b Another trauma case-control study compared patients by blood alcohol level and AWS status and assessed hospital outcomes, supporting the importance of distinguishing alcohol exposure from established withdrawal. ^[2]B3b

Comorbidity may alter both presentation and consequences. In a multinational retrospective cohort of patients hospitalized with alcohol-associated hepatitis, investigators assessed AWS prevalence, predictors, management, and mortality while adjusting for demographic factors and disease severity. ^[30]B2b In a large retrospective comparison, patients with liver disease who underwent CIWA-Ar-based management had a higher prevalence of alcohol use disorder and longer hospital stays than patients without liver disease. ^[142] These findings support lower thresholds for comprehensive evaluation and careful medication selection in medically complex patients, although they do not prove that liver disease independently causes more severe AWS. ^[30]B2b[142]

Treatment implications of severity classification

Benzodiazepines remain the reference treatment within guideline-based management of clinically significant AWS, particularly when seizure or delirium risk is present. ^{[65]A1c[68]B2a} Phenobarbital is a potential alternative or adjunct in selected monitored settings, but a systematic review found that evidence for optimal dosing, comparative efficacy, and safety remains insufficiently standardized. ^[66]A1a Meta-analytic evidence suggests gabapentin may perform favorably against chlordiazepoxide and lorazepam for selected outcomes, while a randomized hospital trial directly studied fixed-dose gabapentin in patients with PAWSS ≥4; these findings do not establish gabapentin as adequate monotherapy for severe or complicated AWS. ^{[70]B2b[71]A1a} Magnesium supplementation was studied as an adjunct in patients with CIWA-Ar scores above 8, but the trial context and adjunctive design do not support using magnesium alone to prevent severe complications. ^[52]A1b Dexmedetomidine has been evaluated retrospectively in critically ill AWS populations for outcomes including intensive-care and hospital length of stay, mortality, and readmission; observational findings cannot establish superiority or replace therapy directed at the underlying withdrawal physiology. ^[69]B3b

Severity classification should therefore combine withdrawal symptoms, trajectory, prior complicated withdrawal, validated risk screening, medication requirements, vital-sign instability, delirium or seizures, comorbidity, and the need for continuous monitoring. ^[65]A1c[144]

Initial emergency assessment

Alcohol withdrawal syndrome (AWS) is a medical emergency that can produce severe complications and is associated with prolonged hospitalization and recurrent alcohol-related admissions. ^[72]B2a Emergency-department (ED) management should therefore begin with rapid assessment of withdrawal severity, complications, coexisting illness, intoxication or other substance use, and the patient’s ability to receive safe observation and follow-up. The recent SAEM GRACE-4 guideline specifically addresses adult ED patients with AWS and alcohol use disorder (AUD) using the GRADE framework. ^[44]A1c Clinical Institute Withdrawal Assessment for Alcohol—revised (CIWA-Ar) scoring is commonly used in hospitalized patients; one multicenter ICU study defined AWS as a CIWA-Ar score of ≥10, although symptom-based scales may be unreliable in delirium, severe agitation, cognitive impairment, or critical illness. ^[172]

Patients with suspected severe or complicated withdrawal require a monitored setting and repeated reassessment for seizures, delirium tremens, autonomic instability, oversedation, respiratory compromise, and alternative diagnoses. The supplied references do not establish a single universal admission threshold, medication protocol, or monitoring duration; disposition should therefore reflect symptom trajectory, prior severe withdrawal, comorbidity, treatment response, and available supervision. ^{[44]A1c[73]A1a[74]A1a}

Pharmacological treatment

Benzodiazepines remain the first-line pharmacological treatment for AWS. ^[74]A1a Treatment should be individualized to clinical severity and response rather than based solely on a numerical score, particularly when delirium or another cause of altered mental status is present. ^{[44]A1c[74]A1a}

Phenobarbital (PB) is an alternative or adjunctive treatment when benzodiazepines are unavailable, insufficient, or unsuitable, but the evidence base remains heterogeneous. ^[74]A1a A 2024 systematic review and meta-analysis compared PB with benzodiazepines in ED AWS and characterized the available evidence as mixed. ^[73]A1a A separate systematic review of direct ED evidence evaluated AWS complications, monitored-setting admission, symptom control, adverse effects, and need for adjunctive medication, but did not establish definitive superiority of PB. ^[74]A1a A broader review identified 20 studies, including 9 ED studies, and concluded that evidence regarding PB’s clinical utility and optimal dosing remains uncertain. ^[66]A1a

PB should therefore be administered only by clinicians familiar with its prolonged sedative effects, drug interactions, airway-risk assessment, and local monitoring requirements. The cited literature does not support a single universally preferred loading or maintenance regimen. ^{[66]A1a[73]A1a[74]A1a} A 2025 single-center retrospective cohort study of 1,178 adults evaluated IV PB monotherapy, IV benzodiazepines, and combination therapy for ED AWS, with admission as the primary outcome and ED length of stay and 72-hour return visits as secondary outcomes; these observational findings should not be interpreted as proof of comparative efficacy. ^[113]B3b

Gabapentin, baclofen, and vigabatrin should not routinely replace benzodiazepines for severe or complicated AWS on the basis of the cited evidence. A systematic review and meta-analysis of gabapentin included 8 retrospective studies involving 2,030 patients and found no randomized trials establishing that gabapentin can replace or reliably reduce benzodiazepine treatment. ^[75]A1a In a randomized trial of 63 patients receiving benzodiazepine-assisted inpatient detoxification, baclofen at 30 mg/day or 60 mg/day for 7 days was studied for its effect on as-needed diazepam use; the authors concluded that existing evidence was insufficient to support baclofen-assisted withdrawal as standard care. ^[77]A1b A placebo-controlled trial randomized 120 residential-withdrawal patients to vigabatrin 2 g/day for 4 days or placebo, assessing diazepam requirement and total dose; this limited setting-specific evidence does not establish vigabatrin as routine acute therapy. ^[78]A1b

Oral ethanol prescribing has been reported in selected UK acute-care settings for patients considered high risk, including those with harmful consumption typically around ≥30 units/day, prior severe withdrawal, withdrawal seizures, or delirium tremens. ^[147]C Because this evidence is retrospective and setting-specific, ethanol should not be generalized as standard ED treatment. ^[147]C

Psychiatric emergencies and post-acute symptoms

After the acute autonomic and neurological syndrome resolves, clinicians should reassess mood, anxiety, cognition, sleep, craving, relapse risk, and safety. Post-acute withdrawal may involve negative affect, anxiety, dysphoria, anhedonia, sleep disturbance, cognitive impairment, irritability, and craving, and symptoms may persist for 4–6 months or longer. ^[16]D5 A systematic review found that persistent craving, sleep disturbance, and anhedonia are clinically relevant components of protracted withdrawal; pooled obsessive-compulsive drinking scores declined from 24.2 at baseline to 18.8 at 1 week, 10.3 at 1 month, and 9.7 at 3 months. ^[47]A1a These symptoms have been associated with recurrent alcohol consumption. ^[16]D5

Patients with agitation, hallucinations, severe anxiety, depressive symptoms, impaired judgment, or suicidal or homicidal thoughts require immediate safety assessment, treatment of concurrent withdrawal, evaluation for delirium or medical causes, and psychiatric consultation or secure placement when indicated. The supplied studies describe post-acute affective and cognitive symptoms but do not directly evaluate suicide-risk instruments, involuntary-treatment criteria, or specific psychiatric emergency interventions; local emergency and mental-health protocols remain necessary. ^{[16]D5[47]A1a}

Evidence limitations

Current evidence supports benzodiazepines as first-line therapy but does not define one universally superior ED regimen. PB is a reasonable evidence-informed alternative or adjunct in selected monitored patients, while evidence for gabapentin, baclofen, vigabatrin, and oral ethanol is insufficient for routine substitution or broad implementation. ^{[66]A1a[73]A1a[74]A1a[75]A1a[77]A1b[78]A1b[147]C}

Definitive care addresses refractory symptoms. Loading BZD protocols may clear symptoms faster than symptom-triggered (69.6% vs 41.7% at 72h) ^[82]A1b. Adjunctive phenobarbital (10 mg/kg IV) reduces ICU admissions from 25% to 8% ^[85]A1b. Dexmedetomidine reduces 12-hour BZD needs but causes bradycardia in 35% of patients ^[87]B3b. Haloperidol is for ICU delirium but must be paired with BZDs to avoid lowering the seizure threshold ^[89]D5.

Pearl: Phenobarbital (10 mg/kg IV) significantly reduces ICU admission rates when added to BZD protocols, but routine magnesium and oxytocin do not improve clinical outcomes in AWS ^{[52]A1b[81]A1b[85]A1b}.

AWS patients are at high risk for torsade de pointes due to electrolyte shifts and QT-prolonging drugs ^[92]C4. Serial ECGs are mandatory when using antipsychotics or in patients with liver disease. Concomitant antibiotics (e.g., metronidazole ) and vasoactive support (e.g., dopamine ) exacerbate QT prolongation ^[92]C4. Aggressive correction of hypokalaemia and hypomagnesemia is required ^[92]C4.

Pearl: Hospitalized patients with AWS often have multiple silent risk factors for proarrhythmic responses; always review the medication profile for QT-prolonging drugs and correct even mild hypokalaemia immediately to prevent torsade de pointes ^[92]C4.

Purpose of assessment

Risk assessment should occur at admission and be repeated when alcohol intake is reduced or stopped, because severe alcohol withdrawal syndrome (SAWS) may cause delirium tremens, withdrawal seizures, or clinically diagnosed severe withdrawal, although most hospitalized patients at risk do not develop SAWS. ^[27]A1a The consequences of missing high-risk withdrawal are substantial, and prediction is clinically important because untreated severe withdrawal has a high mortality rate. ^[27]A1a

Assessment should document the quantity and duration of alcohol use, time and circumstances of the last drink, previous withdrawal symptoms, withdrawal seizures, delirium tremens, and prior complicated detoxification, together with current autonomic or neuropsychiatric symptoms. ^{[27]A1a[50]B2a} The admission history should also identify structural brain disease and other neurological vulnerability, because structural brain lesions were associated with withdrawal seizures in an inpatient cohort receiving treatment for AWS. ^[150]

Risk-stratification tools

The Clinical Institute Withdrawal Assessment for Alcohol (CIWA) and similar symptom scales quantify current withdrawal severity and support symptom-triggered treatment; they do not, by themselves, identify patients who are likely to develop withdrawal or complicated withdrawal before symptoms emerge. ^[50]B2a A patient may therefore require prospective risk assessment even when the initial symptom score is low. ^[50]B2a

PAWSS was developed specifically to predict complicated alcohol withdrawal in medically ill patients after a systematic review of potential clinical predictors. ^[50]B2a It is intended for risk prediction rather than measurement of current withdrawal severity. ^[50]B2a The Alcohol Use Disorders Identification Test–Piccinelli Consumption (AUDIT-PC) was evaluated in hospitalized medical-surgical patients outside intensive care as an admission instrument for predicting subsequent AWS, but the study population and retrospective case–control design limit generalization to critically ill or medically complex patients. ^[8]B3b

The 2018 systematic review assessed the predictive accuracy of symptoms, signs, and risk-assessment tools for SAWS in adults. ^[27]A1a Its clinical implication is that no single historical feature should replace structured assessment and ongoing observation, particularly because the outcome of interest includes several clinically distinct events—delirium tremens, seizure, and severe withdrawal. ^[27]A1a Machine-learning models using admission clinical, laboratory, and sociodemographic information separated mild from moderate-to-severe withdrawal and attempted prediction of delirium tremens and withdrawal seizures, but these models were observational and require external validation before routine bedside use. ^[93]B2c

Monitoring and therapeutic setting

Patients with a credible risk of complicated withdrawal should be managed in a setting capable of frequent reassessment, rapid administration of therapy, protection from falls and seizures, and escalation to higher-acuity care. ^{[27]A1a[50]B2a} The appropriate location depends on current severity, trajectory, comorbidity, nursing observation capacity, and the need for airway, haemodynamic, or ventilatory support. ^{[27]A1a[151]D}

General-hospital protocols have incorporated three linked elements: screening for alcohol-related risk, risk stratification to select fixed-dose or symptom-triggered benzodiazepine treatment, and a symptom scale for treatment monitoring. ^[151]D The Glasgow Assessment and Management guideline was specifically developed for general hospitals and included the Fast Alcohol Screening Test, a risk-stratification strategy, the Glasgow Modified Alcohol Withdrawal Scale, and recommendations for management. ^[151]D Intensive-care practice is heterogeneous; a survey of UK ICU consultants found ambiguity in assessment and management, and most responding units assessed alcohol use primarily by weekly alcohol consumption. ^[176]D Alcohol quantity alone should therefore not be treated as a complete prediction model. ^{[27]A1a[176]D}

Withdrawal severity may evolve after admission. In a cohort of 827 inpatients treated with score-guided, symptom-triggered therapy, a delayed peak in withdrawal severity was associated with withdrawal seizures; structural brain lesions were also significant predictors of seizures. ^[150] Patients whose symptoms intensify, peak late, become difficult to assess, or require escalating sedative doses should be moved to a setting with closer observation and senior clinical review. ^[150]

Capacity, consent, and safety

Capacity should be assessed for each important decision rather than inferred from a diagnosis of alcohol dependence or from intoxication alone. ^{[27]A1a[50]B2a} Severe withdrawal, delirium, seizures, sedation, and fluctuating attention can impair the ability to understand, retain, weigh, or communicate a treatment decision; when capacity is absent, urgent safety-critical treatment should proceed under applicable emergency and substitute-decision frameworks, with reassessment as cognition improves. ^{[27]A1a[50]B2a}

The assessment should record the patient’s ability to participate, the information provided, the agreed monitoring and treatment plan, and the identity of any surrogate or legally authorized decision-maker when required. ^{[27]A1a[50]B2a} Capacity is dynamic: it should be reassessed after stabilization, after recurrent delirium or seizure, and after medication-related sedation. ^[27]A1a[150]

Practical safety standard

A safe plan combines structured admission risk assessment, repeated symptom and neurological observation, explicit seizure and delirium precautions, medication review, nutritional and medical assessment, and a predefined escalation pathway. ^{[27]A1a[50]B2a[151]D} Patients with suspected SAWS, a history of withdrawal seizure or delirium tremens, delayed or rapidly rising severity, structural brain disease, or treatment needs exceeding ward monitoring should receive senior review and consideration of high-dependency or intensive-care management. ^{[27]A1a[150][176]D}

From symptom control to neurobiological treatment

Alcohol withdrawal syndrome (AWS) emerged from recognition that abrupt cessation after prolonged, high-dose alcohol exposure produces compensatory central nervous system hyperexcitability. Chronic alcohol exposure decreases inhibitory GABAergic activity and increases excitatory glutamatergic activity; withdrawal therefore produces a spectrum ranging from autonomic and neuropsychiatric symptoms to seizures and delirium tremens. ^[56]A1c Up to half of people who stop drinking after sustained heavy use may develop AWS. ^[56]A1c Contemporary management has consequently focused on restoring inhibitory tone, limiting excitotoxicity, preventing seizures and delirium, and providing monitored supportive care. ^[56]A1c

Benzodiazepine-centered care

Benzodiazepines became the conventional pharmacological treatment because they augment GABAergic inhibition and can be titrated according to symptom severity. Hospitalized patients are commonly managed with symptom-triggered benzodiazepines guided by the Clinical Institute Withdrawal Assessment for Alcohol, revised version (CIWA-Ar), although fixed-dose approaches are also used. ^[70]B2b The 2020 American Society of Addiction Medicine (ASAM) guideline represented a formal modernization of earlier guidance: it replaced the 2004 ASAM guideline, which had focused on alcohol withdrawal delirium, and addressed adults hospitalized with AWS of any severity. ^[65]A1c This evolution placed AWS treatment within a broader framework of risk assessment, monitoring, medication selection, and prevention of complications. ^[65]A1c

Risk stratification increasingly preceded medication selection. A trauma-center study evaluated combinations of admission characteristics to estimate AWS probability, while a machine-learning analysis used clinical, laboratory, and sociodemographic variables to predict moderate-to-severe withdrawal, delirium tremens, and withdrawal seizures. ^{[31]B2b [93]B2c} These approaches reflect a shift from treating established symptoms alone toward identifying patients at risk for complicated withdrawal before deterioration occurs. ^{[31]B2b [93]B2c}

Expansion of adjunctive and alternative agents

Treatment evolution has included agents intended to reduce benzodiazepine exposure or provide alternatives in selected patients. Gabapentin demonstrated efficacy for withdrawal symptoms and relapse prevention in people with alcohol use disorder, and a randomized clinical trial investigated whether changes in dorsal anterior cingulate cortex GABA and glutamate levels could explain these effects. ^[97]A1b In a separate randomized hospital trial involving patients at risk for complicated withdrawal, fixed-dose gabapentin was compared directly with CIWA-directed benzodiazepines, addressing the limited evidence for gabapentin in hospitalized AWS. ^[70]B2b

Baclofen, a GABA-B receptor agonist, was studied as an adjunct during inpatient benzodiazepine-assisted detoxification. In a single-blind randomized trial, 63 patients received placebo, 30 mg/day, or 60 mg/day of baclofen for 7 days, with diazepam administered as needed according to withdrawal symptoms. ^[77]A1b The study evaluated whether baclofen reduced additional diazepam requirements, but available evidence remained insufficient to establish baclofen-assisted withdrawal as standard treatment. ^[77]A1b Magnesium supplementation was similarly examined as an adjunct because hypomagnesemia has been implicated in AWS severity; a multicenter, double-blind randomized trial enrolled inpatients with baseline CIWA-Ar scores greater than 8 and administered oral magnesium lactate providing 426.6 mg/day for up to 15 days. ^[52]A1b

Other proposed benzodiazepine-sparing strategies have had mixed or limited support. A placebo-controlled randomized trial assigned 120 residential-withdrawal patients to vigabatrin 2 g/day for 4 days or placebo and assessed subsequent diazepam use. ^[78]A1b Transcutaneous electrical acupoint stimulation combined with diazepam was compared with sham stimulation plus diazepam in a double-blind trial of 117 men; symptom, pain, sleep, and daytime-somnolence measures improved in both groups. ^[60]A1b These interventions illustrate the continuing search for adjunctive approaches, but they do not displace benzodiazepines as the established pharmacological foundation. ^{[60]A1b [78]A1b}

Phenobarbital and intensive-care strategies

Phenobarbital has re-entered clinical practice as either an adjunct to benzodiazepines or an alternative monotherapy. ^[101]D5 ASAM recommends phenobarbital in certain clinical contexts, and available evidence is considered sufficient to demonstrate safety and efficacy as an alternative to benzodiazepines, although the overall evidence base remains limited. ^[101]D5 Its long half-life has prompted evaluation of whether a loading dose can effectively self-taper. A retrospective ICU cohort compared phenobarbital with a taper versus no taper after an initial loading dose, reflecting variation in contemporary dosing strategies. ^[154]C

Dexmedetomidine represents another intensive-care adjunct or alternative sedative strategy. A randomized trial comparing intravenous diazepam with dexmedetomidine evaluated hemodynamic effects in 40 patients, while a later retrospective cohort examined dexmedetomidine-associated ICU length of stay, hospital length of stay, mortality, and readmission. ^{[153] [69]B3b} These studies reflect increasing attention to sedation, autonomic control, and resource utilization in severe AWS, but dexmedetomidine does not replace therapy directed at the underlying withdrawal pathophysiology. ^{[153] [69]B3b}

Current emergency and special-population practice

Recent guidance has broadened AWS care beyond inpatient detoxification. The 2024 SAEM GRACE-4 guideline used the GRADE framework and incorporated emergency physicians, addiction specialists, and people with lived experience to address six priority questions concerning adult emergency-department patients with AWS, alcohol use disorder, and cannabinoid hyperemesis syndrome. ^[44]A1c This marks an evolution toward integrated emergency treatment of withdrawal and the underlying alcohol use disorder. ^[44]A1c

Ethanol itself has been reconsidered despite benzodiazepines remaining typical therapy. A 2024 systematic review evaluated oral and intravenous ethanol as alternatives based on its activity at both GABA-A and NMDA receptors. ^[102]A1a A United Kingdom National Health Service service evaluation described oral ethanol prescribing for patients considered at high risk of delirium tremens, with harmful consumption typically at least 30 units/day, or a history of severe withdrawal, withdrawal seizures, or delirium tremens. ^[147]C These data describe implementation and evidence review rather than establishing ethanol as routine care. ^{[102]A1a [147]C}

Special populations have reinforced the need for individualized treatment. In alcohol-associated hepatitis, a multinational retrospective cohort examined AWS prevalence, predictors, management, and clinical impact in hospitalized patients. ^[30]B2b Reports from Japanese hospitals highlight the consequences of delirium tremens and loss of follow-up after acute illness, particularly where specialist addiction services are unavailable. ^[40]C4 Finally, prospective follow-up research has linked severe withdrawal symptoms among patients treated for alcohol use disorder with subsequent suicidal acts, supporting treatment models that connect withdrawal management with ongoing psychiatric and addiction care. ^[103]B2b

Present position

The historical trajectory is therefore from largely symptom-focused benzodiazepine treatment toward risk stratification, protocolized monitoring, phenotype-specific adjuncts, phenobarbital-based regimens, emergency-department pathways, and linkage to longer-term alcohol use disorder care. ^{[44]A1c [65]A1c [101]D5} Despite therapeutic expansion, benzodiazepines remain the reference treatment, while phenobarbital, gabapentin, baclofen, magnesium, vigabatrin, dexmedetomidine, nonpharmacological adjuncts, and ethanol have evidence ranging from promising to insufficient or context-dependent. ^{[52]A1b [56]A1c [70]B2b [77]A1b [78]A1b [101]D5 [102]A1a [153]}

Clinical complications and high-risk comorbidity

Alcohol withdrawal syndrome (AWS) ranges from mild symptoms to seizures, delirium tremens, severe agitation, critical illness, and death; it is associated with substantial morbidity and mortality and is an important cause or complication of hospitalisation.^{[74]A1a[46]A1a[66]A1a[128]} Hospital-based cohorts and protocols therefore focus on early identification of patients at risk for complicated withdrawal, including use of the Prediction of Alcohol Withdrawal Severity Scale (PAWSS), with PAWSS ≥4 defining increased risk in a randomised inpatient trial.^[70]B2b The incidence of hospitalisations involving AWS has been specifically evaluated in a large primary-care population, underscoring that AWS may emerge during hospital care rather than being confined to the presenting complaint.^[128]

Patients with liver disease require particular caution. In a retrospective Mayo Clinic cohort, patients with liver disease who received a CIWA-Ar protocol had a high prevalence of alcohol use disorder and longer hospitalisation than patients without liver disease.^[142] Alcohol-associated hepatitis (AH) is also a high-risk context: a multinational retrospective cohort examined AWS prevalence, predictors, management, and mortality among patients hospitalised with AH, reflecting concern that withdrawal may compound an already severe systemic and hepatic illness.^[30]B2b In patients with alcohol-associated liver disease and severe AWS requiring intensive care, altered drug metabolism increases concern for oversedation, hepatic encephalopathy, and respiratory depression during sedative treatment.^[155]

Pregnancy and the early postpartum period are additional high-risk states. In a Mayo Clinic retrospective series of 8 pregnant patients treated under a CIWA-Ar protocol, AWS was severe, with a median peak CIWA-Ar score of 17; maternal and fetal outcomes, including alcohol-related complications, were assessed.^[140]C The small sample size limits generalisability, but the findings support specialist maternal–fetal assessment and close monitoring when withdrawal occurs during pregnancy or soon after delivery.^[140]C

Age and sex may influence presentation and hospital course. A large Mayo Clinic cohort included 16,190 hospitalisations and 10,092 patients, of whom 30.2% were women, and examined AWS manifestations across four age groups; women and older adults were specifically represented in the analysis.^[36]B2b A separate tertiary alcohol-related disease-unit cohort included 907 patients, including 238 women (26.2%), and evaluated sex-specific AWS, psychiatric, and medical phenotypes.^[125] These observational data support avoiding assumptions that AWS is confined to younger men, although the supplied study summaries do not establish sex-specific differences in AWS severity.^[36]B2b[125]

Treatment-related harm and choice of sedative

Benzodiazepines remain standard first-line therapy, but their use can cause oversedation, respiratory depression, and delirium, and treatment may be insufficient in refractory withdrawal.^{[74]A1a[46]A1a[136]} Phenobarbital has been studied as an alternative or adjunct because of concern about benzodiazepine-refractory AWS and medication-related complications; however, systematic reviews concluded that the evidence base remains heterogeneous and that optimal dosing and comparative safety are incompletely defined.^{[74]A1a[46]A1a[66]A1a} Direct emergency-department evidence has examined AWS complications, monitored-setting admission, symptom control, adverse effects, and adjunctive medication use, but does not justify assuming that phenobarbital is universally safer than benzodiazepines.^[74]A1a

In trauma populations, retrospective comparisons evaluated phenobarbital monotherapy or low-dose oral phenobarbital against benzodiazepine-based regimens because of concerns about benzodiazepine-associated delirium and refractory withdrawal.^[136] A critically ill surgical-trauma cohort similarly assessed AWS-related complications after phenobarbital, defining complications as severe agitation, delirium tremens, or seizures after treatment initiation.^[131] These studies are observational and context-specific; phenobarbital remains capable of causing excessive sedation and respiratory compromise, particularly when combined with other central nervous system depressants.^{[66]A1a[74]A1a}

In patients with alcohol-associated liver disease and severe AWS in the ICU, a retrospective MIMIC-IV cohort compared initial phenobarbital with benzodiazepines using inverse-probability weighting.^[155] The study was designed to evaluate safety and effectiveness in a population vulnerable to drug accumulation, hepatic encephalopathy, and respiratory depression; its retrospective design means that treatment selection and residual confounding remain important limitations.^[155]

Gabapentin is an evidence-based option for selected outpatient withdrawal scenarios, but its role in hospitalised patients remains less certain.^{[70]B2b[75]A1a} An open-label randomised trial of 88 hospitalised adults at risk for complicated AWS compared a fixed-dose gabapentin taper with CIWA-directed benzodiazepines.^[70]B2b A systematic review and meta-analysis found 8 retrospective studies involving 2,030 patients, but no randomised studies were available in the included evidence base; outcomes included symptom resolution, benzodiazepine exposure, serious withdrawal-related complications, and length of stay.^[75]A1a Gabapentin should therefore not be assumed to prevent severe withdrawal complications in high-risk or complicated AWS without appropriate monitoring.^{[70]B2b[75]A1a}

Dexmedetomidine may reduce autonomic symptoms or CIWA-Ar scores, but it does not replace definitive anticonvulsant therapy for AWS.^[69]B3b A retrospective cohort compared AWS management with and without dexmedetomidine, assessing ICU stay, hospital length of stay, mortality, and readmission; causal conclusions are limited by the non-randomised design.^[69]B3b

Systems-related and iatrogenic risk

Symptom-triggered treatment can reduce unnecessary sedative exposure when patients can be assessed reliably, but protocol performance depends on the validity of the assessment tool and staff implementation.^[130] A modified MINDS-based protocol has been evaluated on a general medical ward rather than only in the ICU, while CIWA-Ar remains widely used in hospital protocols.^[130][140]C Electronic order-set review has demonstrated variation in hospital AWS pathways and assessed concordance with guidance across laboratory assessment, severe-withdrawal risk assessment, symptom assessment, treatment, and associated management.^[149] In practice, harm may result from both undertreatment—allowing seizures, delirium tremens, or severe agitation—and overtreatment, producing oversedation, respiratory depression, delirium, prolonged monitoring, or avoidable ICU-level care.^{[74]A1a[46]A1a[66]A1a}

Studies of ICU sedation that excluded AWS cannot be used to infer sedation outcomes for withdrawal patients.^[141]C Similarly, observational studies of AWS-related demographics, liver disease, pregnancy, or treatment protocols identify associations rather than proving that a particular drug or protocol prevents complications.^{[30]B2b[36]B2b[69]B3b[125][128][136][142][155]}

Overall course and severity

Alcohol withdrawal syndrome (AWS) has a heterogeneous clinical course: most patients experience mild withdrawal, whereas a smaller proportion develop withdrawal seizures or delirium tremens (DT). ^[137] In an emergency-department derivation study, severe AWS was defined as a composite of DT, seizure, or high benzodiazepine use; the Alcohol Withdrawal Triage Tool was developed to identify patients likely to require hospital admission. ^[137] A separate machine-learning study used admission clinical, laboratory, and sociodemographic variables to predict moderate-to-severe withdrawal, DT, and withdrawal seizures, and reported that mild and more severe cases could be distinguished with statistically significant, although highly variable, performance. ^[93]B2c

Withdrawal severity is associated with hospital resource use and adverse outcomes. In a retrospective cohort of 2,464 hospital stays, maximum withdrawal severity scores were examined in relation to length of stay and in-hospital mortality; patients categorized as having mild scores (<6), moderate scores (6–9), or severe scores (>9) had median hospital stays of 5.93 days and progressively longer durations as severity increased, although the supplied abstract does not provide the remaining group-specific estimates. ^[58]B3b The maximum score was evaluated both across the admission and during the first 3 days of withdrawal, supporting early severity assessment as clinically relevant. ^[58]B3b The CIWA-Ar follows the clinical course of AWS in aggregate, according to a systematic review and meta-analysis, although the review found substantial variation among studies and did not establish that any specific treatment consistently produces superior symptom-score reduction. ^[55]A1a

Factors associated with complicated or prolonged withdrawal

Hospitalized patients with alcohol-associated hepatitis may be particularly vulnerable to clinically important AWS. A multinational retrospective cohort evaluated its prevalence, predictors, management, and mortality impact in patients hospitalized with alcohol-associated hepatitis; the study specifically adjusted analyses for demographic variables and disease severity, but the supplied abstract does not report the resulting prevalence, predictors, or mortality estimates. ^[30]B2b In a Japanese cohort of 88 patients with alcoholic hepatitis, investigators evaluated DT, acute-on-chronic liver failure, related conditions, and patient outcomes; the report highlights that loss of contact with some patients after DT may lead to missed critical events, emphasizing the need for continued follow-up after delirium improves. ^[40]C4

Age and sex may influence presentation and hospital course. A 2019–2022 cohort comprising 16,190 hospitalizations, representing 10,092 patients aged ≥21 years, included 30.2% women and compared patients aged 21–39, 40–64, 65–74, and ≥75 years. ^[36]B2b The 40–64-year group was the reference category for analysis; the supplied abstract establishes the study population and age-stratified design but does not provide the sex- and age-specific outcome estimates. ^[36]B2b

Treatment response and implications for prognosis

Benzodiazepines remain the principal comparator and were used in national Veterans Health Administration practice across fixed-dose, symptom-triggered, and front-loading strategies. ^[5]B2c In 6,938 medical inpatients with AWS, 41.9% received fixed-dose treatment, 40.8% symptom-triggered treatment, and 17.3% front-loading treatment; the study evaluated cumulative benzodiazepine exposure, ICU admission, and intubation, although the supplied abstract does not provide the adjusted outcome estimates. ^[5]B2c

Early, focused treatment may affect utilization in severe AWS. In a pre–post cohort, severe AWS was defined as diazepam use of >30 mg, and focused therapy as administration of >50% of total diazepam use during the first 24 hours. ^[157]C The study tested whether this approach reduced hospital length of stay; the supplied abstract does not report the final effect estimate. ^[157]C In the ICU, a randomized study found that adding dexmedetomidine to symptom-triggered benzodiazepines was designed to provide arousable sedation and adrenergic control without respiratory depression, but the supplied evidence does not provide definitive mortality or long-term outcome results. ^[156]

A 2023 network meta-analysis of 41 studies involving 4,187 participants found no significant difference in CIWA-Ar reduction between benzodiazepines and other evaluated medications or combinations. ^[57]A1a Anticonvulsants combined with benzodiazepines were associated with a shorter ICU stay than benzodiazepines alone, with a pooled mean difference of −1.71 days (95% CI, −2.82 to −0.59). ^[57]A1a Individual randomized studies found that baclofen and chlordiazepoxide were compared in uncomplicated AWS, oxytocin was tested as an adjunct to symptom-triggered oxazepam, vigabatrin was evaluated as a diazepam-sparing agent, and transcutaneous electrical acupoint stimulation was combined with diazepam; these studies primarily assessed symptom control, benzodiazepine exposure, sleep, or short-term treatment response rather than long-term prognosis. ^{[107]A1b[81]A1b[78]A1b[60]A1b}

Severe and ICU withdrawal

Phenobarbital use in critically ill adults is generally studied in patients requiring escalation of AWS treatment. ^[172] A multicenter propensity-matched cohort defined ICU AWS using CIWA-Ar ≥10 and examined phenobarbital as a marker of severe or refractory withdrawal, treatment escalation, time to discharge, and safety outcomes; the supplied abstract does not provide the matched effect estimates. ^[172] A 2026 systematic review and meta-analysis compared phenobarbital-based with benzodiazepine-based pathways in critically ill adults and specifically examined whether pathway design and timing of phenobarbital influenced outcomes; the supplied abstract does not include the pooled results. ^[177] Retrospective studies likewise compared phenobarbital with benzodiazepine monotherapy, or phenobarbital with dexmedetomidine as adjuncts, for AWS resolution, length of stay, mechanical ventilation, and safety outcomes, but their nonrandomized designs limit causal interpretation. ^{[126][114]B3b}

Overall, the available evidence supports severity-stratified monitoring: higher withdrawal scores, suspected seizures or DT, escalating sedative requirements, ICU transfer, and significant medical comorbidity identify patients at greater risk for prolonged hospitalization or complications. ^{[58]B3b[137][93]B2c[30]B2b[172]} However, the supplied studies predominantly address short-term symptom control, ICU or hospital utilization, and treatment escalation; they do not establish reliable long-term abstinence, recurrence, or mortality estimates for AWS as a whole. ^{[55]A1a[57]A1a[177]}

Scope and evidence limitations

Alcohol withdrawal syndrome (AWS) in pregnancy and the early postpartum period is an uncommon but potentially severe presentation for which the evidence base remains limited. In a retrospective Mayo Clinic review of patients managed with a Clinical Institute Withdrawal Assessment for Alcohol—Revised (CIWA-Ar) protocol from 2019 to 2022, only 8 pregnant patients were identified. Their median peak CIWA-Ar score was 17 (interquartile range, 14), indicating clinically significant withdrawal in this small cohort. Pregnancy, labour, and neonatal outcomes were reviewed, but the supplied study evidence does not provide sufficient numerical detail to establish specific fetal, neonatal, or maternal complication rates. ^[140]C

The available treatment evidence should not be assumed to apply directly to pregnancy. A systematic review of anti-seizure medications (ASMs) included 24 randomized trials involving 2223 adults aged over 18 years, but the supplied evidence does not identify pregnancy-specific participants or outcomes. ^[110]A1a Similarly, contemporary phenobarbital studies evaluated adults in emergency, ward, or intensive-care settings and do not establish safety or efficacy during pregnancy or lactation. ^{[113]B3b[114]B3b[154]C[164][165][172]} Consequently, medication selection in pregnancy requires individualized multidisciplinary assessment involving obstetrics, psychiatry, addiction medicine, anesthesia, and neonatology; this is an evidence-gap statement rather than evidence for a particular drug. ^{[110]A1a[140]C}

Pregnancy and early postpartum care

Pregnant patients presenting with suspected AWS should receive urgent assessment for withdrawal severity, seizures, delirium, medical comorbidity, nutritional deficiency, and fetal or neonatal concerns. The pregnancy cohort demonstrates that clinically substantial withdrawal occurs in this population, although its small size prevents reliable prediction of individual outcomes. ^[140]C CIWA-Ar-based protocols have been used in pregnant patients, but CIWA-Ar is not specific to pregnancy and should be interpreted alongside objective examination and obstetric assessment. ^[140]C[166]

The early postpartum period should remain a high-risk transition point because the cited pregnancy study specifically examined severe withdrawal during pregnancy or early postpartum, while the available abstract does not provide enough detail to quantify postpartum risk separately. ^[140]C Perinatal psychiatric assessment should address alcohol-use-disorder severity, relapse risk, suicidality, psychiatric comorbidity, safeguarding, social supports, and the safety of the pregnant or postpartum patient and infant; however, the references supplied here do not provide outcome data for these psychiatric domains. ^[140]C

Diagnostic considerations in special populations

Withdrawal symptoms may be mimicked or obscured by other acute conditions. In postoperative patients, physiological responses to surgery and systemic inflammatory response syndrome overlap with AWS features, and the commonly used CIWA-Ar scale may therefore produce false-positive assessments; the postoperative study emphasizes that the scale has been validated primarily in detoxification settings rather than broadly across acute hospitals. ^[166] This limitation is particularly relevant when pregnancy, operative delivery, postpartum complications, or other medical illness complicate symptom interpretation. ^[140]C[166]

Neurological injury creates an additional diagnostic and safety challenge because agitation, altered consciousness, seizures, and sedation may reflect the injury rather than withdrawal or may be worsened by treatment. A retrospective ICU study specifically compared phenobarbital with symptom-triggered benzodiazepines in patients with primary neurological injuries, with oversedation defined using a Richmond Agitation Sedation Scale-based outcome; the study supports the need for careful monitoring but does not establish pregnancy-specific safety. ^[164]

Trauma patients may also have overlapping causes of tachycardia, agitation, pain, and altered mental status. In a retrospective cohort of 3896 adult trauma admissions, patients were categorized by blood alcohol concentration or AWS, illustrating the clinical relevance of distinguishing intoxication, withdrawal, and trauma-related physiology. ^[2]B3b Alcohol-associated infection can further confound presentations: among 1359 community-acquired bacterial meningitis episodes, 88 (6%) occurred in patients with alcoholism; seizures were presenting symptoms in 18%, and pneumonia coexisted in 23%. ^[48]B2b

Medical comorbidity and treatment monitoring

Patients with alcohol-related liver disease may experience severe complications alongside withdrawal. A Japanese retrospective study of 88 patients hospitalized with alcoholic hepatitis examined delirium tremens, acute-on-chronic liver failure, and outcomes, highlighting the need to coordinate withdrawal management with hepatology and critical-care assessment. ^[40]C4 Low magnesium is clinically relevant: in a retrospective AWS cohort, 64 of 380 patients (17%) died within one year, and the study evaluated the association between serum magnesium and mortality. ^[160] Nutritional deficiencies also require attention; an observational ICU study found vitamin C deficiency was common in patients with alcohol-use disorders, while thiamine replacement was regarded as standard care in the study context. ^[161]C

Older adults may have increased vulnerability to sedation, delirium, falls, and medication accumulation, although the supplied multicentre study of patients aged ≥80 years evaluated alcohol use and in-hospital complications rather than pregnancy or AWS-specific treatment. ^[163] Across special populations, symptom-triggered protocols, phenobarbital strategies, and benzodiazepine regimens have been studied mainly in nonpregnant adults, with observational evidence varying by setting and severity. ^{[111]B3b[113]B3b[114]B3b[127][143][154]C[162]C[165][172]} These data should therefore inform—but not replace—individualized perinatal risk assessment and close maternal, fetal, and neonatal monitoring. ^{[110]A1a[140]C}

Prevention and risk recognition

Alcohol withdrawal syndrome (AWS) is potentially life-threatening, can complicate hospitalization, and is a preventable cause of alcohol-related hospital utilization and prolonged inpatient care.^[72]B2a[143] Prevention begins with systematic identification of alcohol use and withdrawal risk at admission, particularly because hospitalized patients may develop AWS after presentation rather than arrive with established symptoms.^[8]B3b In a retrospective primary-care cohort from 2018–2022, hospitalizations involving AWS were evaluated across patient characteristics, supporting the use of routinely collected primary-care alcohol-screening data to identify populations at risk.^[128]

All hospitalized patients should undergo structured assessment of alcohol use, recent reduction or cessation, previous withdrawal complications, and current symptoms when clinically appropriate.^{[8]B3b[115]A1a[143]} ICU patients require particular vigilance because AWS and delirium tremens are common enough to warrant dedicated screening, prophylaxis, and treatment strategies, although the critical-care literature has historically lacked uniformly accepted practice guidelines.^[115]A1a Older adults may be especially vulnerable to alcohol-related harm: a multicentre study of adults aged ≥80 years assessed alcohol use and alcohol use disorder using structured interviews, AUDIT, and CAGE, highlighting the feasibility and importance of systematic assessment in this group.^[163]

Screening for withdrawal risk

The AUDIT-PC was evaluated as an admission tool for predicting subsequent AWS among medical–surgical inpatients outside intensive care.^[8]B3b It is a consumption-focused instrument and should be interpreted as a risk-stratification aid rather than a diagnostic substitute for serial clinical assessment.^[8]B3b Earlier literature identified a gap between instruments that quantify current withdrawal severity, such as the Clinical Institute Withdrawal Assessment for Alcohol (CIWA), and instruments that predict future complicated withdrawal.^[50]B2a

The Prediction of Alcohol Withdrawal Severity Scale (PAWSS) was developed to address this gap by combining clinical risk factors associated with moderate-to-severe or complicated AWS.^[50]B2a It was designed for medically ill patients and underwent a pilot validity assessment, but the cited publication is a systematic review and pilot study rather than definitive evidence for universal use in every setting.^[50]B2a Risk factors for severe AWS have also been examined in an acute-hospital case–control population of 382 cases and 382 controls, although the supplied abstract does not provide the complete list or effect estimates.^[35]B3b Trauma-specific retrospective research similarly evaluated 1,011 adults admitted to a level I trauma centre, using admission blood alcohol concentration and heavy drinking—defined as daily drinking or >7 drinks per week—among candidate risk conditions.^[31]B2b

Machine-learning models have been investigated as an adjunct to clinical risk assessment.^[93]B2c In two detoxification wards, models were developed using 121 clinical, laboratory, and sociodemographic variables in cohorts of 389 and 805 alcohol-dependent patients to predict moderate-to-severe withdrawal, delirium tremens, and withdrawal seizures.^[93]B2c The models separated mild from more severe withdrawal with statistically significant, although highly variable, performance; they should therefore be regarded as investigational rather than a replacement for clinical examination and monitoring.^[93]B2c

Early intervention and monitored pathways

A practical prevention strategy is universal screening followed by targeted serial assessment and protocolized treatment. One hospital implemented universal AUD screening in noncritical-care admissions, used PAWSS for initial risk identification, applied the Glasgow Modified Alcohol Withdrawal Scale (GMAWS) to patients considered at risk, and treated patients according to a predetermined protocol.^[143] This retrospective cohort study examined length of stay, benzodiazepine exposure, and AWS-attributable adverse events, but the supplied abstract does not report the final effect estimates.^[143] Evaluation of electronic health-record AWS order sets likewise found substantial variation in laboratory assessment, severe-withdrawal risk assessment, symptom assessment, treatment, and associated management changes, indicating that protocol availability does not necessarily ensure guideline-concordant care.^[149]

Early pharmacological intervention should be individualized according to withdrawal severity, medical comorbidity, prior seizures or delirium, monitoring capacity, and suitability for inpatient versus outpatient care.^{[115]A1a[50]B2a} Benzodiazepines remain an established treatment approach for moderate-to-severe AWS; a randomized, double-blind study compared lorazepam 8 mg/day with chlordiazepoxide 80 mg/day, both down-titrated to zero over 8 days, in 100 male inpatients with moderately severe uncomplicated AWS.^[116]A1b The cited abstract does not provide the comparative outcome data, so it does not establish superiority of either regimen.^[116]A1b

Outpatient detoxification requires screening for eligibility, daily or otherwise close monitoring, reliable follow-up, and rapid escalation pathways.^[117]C4[168] In an open-label case series, nine eligible patients completed a maximum 7-day outpatient regimen of levetiracetam, up to 2,500 mg/day, plus tiapride, up to 300 mg/day, with daily AWSS assessment.^[117]C4 A separate open-label observational study evaluated levetiracetam at 500–4,000 mg/day for up to 7 days with diazepam rescue and daily AWSS assessment, including 6-month follow-up.^[168] These small, nonrandomized studies do not establish these regimens as standard prophylaxis.^[117]C4[168] A 2026 pilot case series similarly evaluated a fixed-dose, 6-day gabapentin taper for carefully selected low-risk patients, with doses from 1,800 mg tapered to 300 mg and follow-up on days 2–3, day 7, and 1 month; its case-series design limits generalizability.^[169]C

Baclofen has been evaluated in Cochrane reviews for AWS efficacy and safety, including a review updated through 2012.^{[13]A1a[14]A1a} The cited reviews address baclofen as a possible treatment, but do not by themselves support routine prophylactic use. Economic evidence remains limited: a 2025 systematic review screened 6,347 records, assessed 5,250 after duplicate removal, and included only eight studies, emphasizing the need to balance clinical effectiveness, safety, and resource use.^[72]B2a

Practical priorities

Use structured alcohol screening, identify high-risk patients before symptoms escalate, perform serial symptom assessments, and apply monitored, protocolized treatment with clear escalation criteria.^{[8]B3b[50]B2a[143][149]} Patients with suspected or evolving complicated withdrawal should not be managed solely through an outpatient pathway.^{[50]B2a[115]A1a} Any prophylactic or early-treatment protocol should be locally validated, regularly audited, and supported by staff capable of recognizing seizures, delirium tremens, oversedation, and other medical complications.^{[115]A1a[143][149]}